Congenital Central Hypoventilation Syndrome Type 1 With or Without Hirschsprung Disease

Congenital Central Hypoventilation Syndrome (CCHS) is a rare condition where the brain’s automatic breathing control does not work well, especially during sleep. A person with CCHS can look “fine” while awake, but when they fall asleep their breathing becomes too slow or too shallow, so oxygen can drop and carbon dioxide can rise. CCHS is also part of a wider problem called autonomic nervous system dysregulation, which means the “automatic” body functions (breathing drive, heart rhythm control, temperature control, sweating, gut movement, and some eye reactions) can be abnormal. Most confirmed CCHS is caused by a disease-causing change (pathogenic variant) in the PHOX2B gene. NCBI+2American Thoracic Society+2

Congenital Central Hypoventilation Syndrome (CCHS) is a rare condition that starts at birth. The lungs and air tubes can look normal, but the brain’s automatic breathing control does not work well, especially during sleep. Because of this, the person breathes too shallowly and too slowly, so oxygen can drop and carbon dioxide (CO₂) can rise. CCHS is part of a bigger problem called “autonomic nervous system dysfunction,” meaning the body may also struggle with automatic tasks like heart-rate control, temperature control, sweating, and bowel movement. Most confirmed cases are linked to a change (variant) in the PHOX2B gene, and genetic testing helps confirm the diagnosis. Some people also have Hirschsprung disease, where part of the bowel lacks nerve cells and cannot move stool normally; this combination is often called Haddad syndrome. NIDDK+4Genetic Disease Center+4NCBI+4

Some people also have Hirschsprung disease, which is a condition where part of the large intestine is missing normal nerve cells, leading to severe constipation or bowel blockage. When CCHS and Hirschsprung disease occur together, it is often called a special combined form (Haddad syndrome). Genetic Disease Center+2Orpha+2

Other names

CCHS is also known by several other names used in clinics and in older medical papers. American Thoracic Society+1

• Congenital central hypoventilation syndrome (CCHS) NCBI+1

• Ondine’s curse / Ondine syndrome (older name; still seen in many sources) American Thoracic Society+1

• Central hypoventilation syndrome, congenital, 1 (rare-disease naming) Genetic Disease Center

• CCHS with Hirschsprung disease (Haddad syndrome) Orpha+1

Types (list view)

• Classic (neonatal-onset) CCHS: symptoms usually begin in the newborn period, often very early, and breathing support is commonly needed during sleep and sometimes during wakefulness too. Genetic Disease Center+1

• Later-onset CCHS (LO-CCHS): milder form where breathing problems may be mainly during sleep and may be noticed later in childhood or even adulthood. NCBI+1

• CCHS with Hirschsprung disease (Haddad syndrome): CCHS plus bowel nerve problems causing severe constipation/obstruction. Orpha+2Genetic Disease Center+2

• CCHS with neural-crest tumors: some people have CCHS plus tumors such as neuroblastoma or related tumors. Genetic Disease Center+1

• PHOX2B “PARM” type: CCHS caused by a polyalanine repeat expansion mutation in PHOX2B (the most common genetic pattern). NCBI+1

• PHOX2B “NPARM” type: CCHS caused by other PHOX2B changes (like frameshift, nonsense, missense, or splice changes), which can sometimes be linked with more complex features. NCBI+1

Causes (20)

1. PHOX2B polyalanine repeat expansion (PARM). This is the most common cause of confirmed CCHS. It changes a repeat section in PHOX2B so the brain’s autonomic control of breathing develops or functions abnormally. NCBI+1

2. PHOX2B frameshift variants (a type of NPARM). A frameshift is a DNA change that shifts the “reading frame,” often making an abnormal protein. In CCHS, frameshift variants can disrupt PHOX2B function and worsen automatic breathing control. NCBI+1

3. PHOX2B nonsense variants (a type of NPARM). A nonsense change can create an early “stop” signal, producing a shortened protein that does not work normally. This can cause the CCHS pattern of sleep-related hypoventilation and autonomic problems. NCBI+1

4. PHOX2B missense variants (a type of NPARM). A missense variant swaps one amino acid for another, which can damage PHOX2B function and lead to CCHS features, sometimes with variable severity between people. NCBI+1

5. PHOX2B splice-site variants (a type of NPARM). Splice-site changes can cause the gene message to be cut and joined incorrectly, leading to an abnormal PHOX2B protein and impaired autonomic breathing control. NCBI+1

6. Whole-gene or exon deletions involving PHOX2B. Some people have deletions (missing DNA) that remove all or part of PHOX2B (often discussed as exon 3 deletions in clinical testing). These can cause CCHS but may require special testing methods to detect. NCBI+1

7. De novo (new) genetic change in the child. In many cases, the PHOX2B change is new in the affected person and was not inherited in the usual way from a parent. Genetic Disease Center+1

8. Autosomal dominant inheritance. CCHS is typically inherited in an autosomal dominant pattern, meaning one altered copy of PHOX2B can be enough to cause disease in a family. NCBI+1

9. Parental mosaicism. Sometimes a parent has the PHOX2B change in only some cells (mosaicism) and may have mild or even unrecognized symptoms, but can still pass the change to a child. NCBI+1

10. Reduced penetrance in rare situations. Rarely, some PHOX2B patterns may show reduced penetrance (the gene change is present but symptoms can be mild or delayed), which can make family patterns confusing. NCBI+1

11. Repeat length affects severity (genotype–phenotype link). In PARM-type CCHS, the number of alanine repeats can be linked with how severe breathing support needs are, so the “size” of the expansion can matter clinically. NCBI+1

12. Neural-crest/autonomic development disruption (core mechanism). PHOX2B is important for development of parts of the autonomic nervous system; when it is altered, multiple automatic body controls can be affected, not only breathing. American Thoracic Society+1

13. Cause of the Hirschsprung association (shared nerve-development pathway). Hirschsprung disease happens because bowel nerve cells do not develop or migrate normally; CCHS can be linked because both involve nerve development pathways related to autonomic function. Orpha+1

14. Genetic modifiers in syndromic Hirschsprung disease. In CCHS with Hirschsprung disease, other genes/pathways involved in bowel nerve development (described in medical literature as modifiers) may influence whether Hirschsprung disease appears along with PHOX2B-related CCHS. American Thoracic Society+1

15. Neural-crest tumor association (shared cell origin). Some people with CCHS develop tumors like neuroblastoma or ganglioneuroma; these tumors come from neural-crest-related tissues, which fits the broader “autonomic/neural-crest” theme in CCHS. Genetic Disease Center+1

16. Sedatives or other breathing-depressant medicines can unmask mild cases. In some mild/later-onset forms, symptoms may become clear when a person is exposed to respiratory depressants (for example, certain anesthesia or sedating medicines), because the already-weak automatic drive is pushed lower. NCBI+1

17. Severe lung infection or serious illness can unmask mild/later-onset CCHS. Some people with very mild CCHS may not be recognized until a major illness stresses breathing control and reveals abnormal CO₂/oxygen handling during sleep. NCBI+1

18. Brainstem structural problems (important alternative cause to rule out). Central hypoventilation can also be caused by brainstem injury or malformations; clinicians must exclude these before calling a case “congenital central hypoventilation syndrome.” Lurie Children’s+1

19. Neuromuscular weakness (important alternative cause to rule out). Weak breathing muscles from neuromuscular disorders can cause hypoventilation, but this is a different mechanism than CCHS, so testing is done to separate them. Lurie Children’s+1

20. Severe obstructive sleep apnea or chronic lung disease (important alternative causes to rule out). Low oxygen and high carbon dioxide during sleep can also come from airway blockage or lung disease, so CCHS diagnosis requires showing the pattern is not explained by these more common problems. Lurie Children’s+1

Symptoms (15)

1. Sleep-related hypoventilation. The key symptom is breathing that becomes too shallow or too slow during sleep, because the automatic breathing drive is weak, even without airway blockage. American Thoracic Society+1

2. High carbon dioxide (hypercapnia), especially during sleep. When breathing is too weak, carbon dioxide builds up, and this can be measured on sleep testing or blood gas testing. NCBI+1

3. Low oxygen (hypoxemia), especially during sleep. Oxygen levels may drop, sometimes without the person waking up or “feeling” short of breath, because the body’s alarm response can be blunted. NCBI+1

4. Bluish skin or lips (cyanosis). Some infants (and sometimes older patients) may look blue during sleep because oxygen is low, which can be an early warning sign. Genetic Disease Center+1

5. Reduced response to low oxygen and high CO₂. Many people with CCHS do not increase breathing normally when oxygen falls or carbon dioxide rises, which is why monitoring and assisted ventilation are often needed. American Thoracic Society+1

6. Breathing pauses (apnea) or very irregular breathing during sleep. Sleep studies may show central apneas (pauses without airway blockage) or sustained hypoventilation patterns. NCBI+1

7. Abnormal heart rhythm control (bradycardia or long pauses). The autonomic system controls heart rate; some patients can have significant rhythm issues, so heart monitoring is part of routine evaluation. NCBI+1

8. Blood pressure instability. Some people have difficulty regulating blood pressure, which may show as unusual drops, spikes, or abnormal responses to posture changes. Genetic Disease Center+1

9. Temperature control problems. The body may have trouble keeping normal temperature (for example, low body temperature or poor fever responses), because automatic regulation is affected. Genetic Disease Center+1

10. Sweating abnormalities. Sweating may be too much, too little, or “oddly timed,” reflecting autonomic dysregulation rather than a skin disease. Genetic Disease Center+1

11. Eye and pupil findings. Some patients show eye-related autonomic features (such as abnormal pupil reactions or other eye abnormalities), which can be part of the broader syndrome picture. Genetic Disease Center+1

12. Severe constipation or bowel obstruction (Hirschsprung disease). In the combined form, part of the colon lacks nerve cells, leading to severe constipation, swollen belly, feeding difficulty, or intestinal blockage. Orpha+1

13. General gut movement problems even without Hirschsprung disease. Some people have abnormal gastrointestinal motility (slow movement of food and stool) due to autonomic control problems. American Thoracic Society+1

14. Learning, attention, or school difficulties. Neurocognitive issues can happen, sometimes related to early life oxygen/CO₂ instability and the broader autonomic condition, so monitoring development and school needs is recommended. NCBI+1

15. Neural-crest tumors (for example neuroblastoma). A minority of patients can develop tumors like neuroblastoma or related tumors, so clinicians stay alert for warning signs and may use screening based on risk. Genetic Disease Center+1

Diagnostic tests (20)

Physical exam (4)

1. Focused breathing and sleep history + observation. Clinicians look for a pattern where breathing worsens mainly during sleep, often noticed by caregivers as “quiet breathing,” shallow breathing, or color change. American Thoracic Society+1

2. Vital signs pattern (oxygen saturation trends, breathing rate, heart rate). Even basic exam data can show unusual patterns, like low oxygen during sleep or unusual heart rate control, which supports further testing. Lurie Children’s+1

3. Autonomic signs on exam. The clinician checks for clues of autonomic dysregulation such as temperature instability, sweating issues, and abnormal pupil/eye responses, which often travel with CCHS. American Thoracic Society+1

4. GI exam for constipation/obstruction signs. A swollen abdomen, severe constipation history, or feeding problems can suggest Hirschsprung disease in a person suspected of CCHS. Orpha+1

Manual / bedside tests (4)

5. Continuous pulse oximetry (spot or overnight). A simple sensor tracks oxygen levels over time and can show repeated or sustained drops during sleep that need deeper evaluation. Lurie Children’s+1

6. End-tidal CO₂ (capnography) monitoring. Measuring exhaled CO₂ (often with a visible waveform) helps detect hypoventilation, especially during sleep, and is used in comprehensive physiologic assessments. NCBI+1

7. Respiratory inductance plethysmography (chest/abdomen belts). Belts around the chest and abdomen show breathing effort and pattern, helping separate central hypoventilation from airway blockage patterns. NCBI+1

8. Autonomic bedside screening (selected noninvasive tests). Many centers do noninvasive autonomic testing (age-appropriate) to map how widespread autonomic dysregulation is, because CCHS is more than “only breathing.” NCBI+1

Lab and pathological tests (6)

9. Arterial or capillary blood gas (ABG/CBG). This measures oxygen and carbon dioxide directly in blood and can confirm chronic or sleep-related CO₂ retention (hypercapnia). Lurie Children’s+1

10. Serum bicarbonate (metabolic compensation clue). Long-term CO₂ retention can raise bicarbonate as the body tries to balance acid-base status, so this lab can support the picture of chronic hypoventilation. Lurie Children’s+1

11. PHOX2B genetic testing (disease-defining test). A diagnosis of CCHS is established when suggestive clinical findings are paired with a disease-causing PHOX2B variant on molecular testing. NCBI+2American Thoracic Society+2

12. Stepwise PHOX2B testing strategy (screening → sequencing → deletion/duplication testing). Guidelines describe stepwise testing to detect common PARMs first and then look for other PHOX2B changes, including larger deletions/duplications that sequencing alone can miss. Lurie Children’s+1

13. Complete blood count (CBC) and hematocrit (polycythemia check). Chronic low oxygen can lead the body to make more red blood cells, so blood counts are used in surveillance and overall assessment. NCBI+1

14. Rectal biopsy (pathology) for Hirschsprung disease. If Hirschsprung disease is suspected, a rectal biopsy can confirm missing nerve cells in the bowel wall, which is a key diagnostic step. American Thoracic Society+1

Electrodiagnostic tests (3)

15. Polysomnography (sleep study). This is the main physiologic test for sleep-related breathing disorders. It can document hypoventilation, oxygen drops, CO₂ rises, and central apneas, while also staging sleep. NCBI+1

16. ECG and extended rhythm monitoring (Holter). Because significant rhythm pauses can occur in CCHS, extended monitoring (often 72-hour Holter in guidelines) may be used to detect dangerous pauses. NCBI+2Lurie Children’s+2

17. EEG (when clinically indicated). If there are events that could be seizures or unusual spells, EEG can help rule in/out seizures as a separate issue and help interpret sleep-related events. Lurie Children’s+1

Imaging tests (3)

18. Brain/brainstem MRI. Imaging can help rule out structural causes of central hypoventilation (like brainstem lesions), which is important before confirming CCHS as a genetic autonomic disorder. Lurie Children’s+1

19. Echocardiogram (heart ultrasound). An echo checks for effects of chronic breathing problems on the heart (such as signs of pulmonary hypertension or right-heart strain), and is part of ongoing surveillance recommendations. NCBI+1

20. Contrast enema imaging for Hirschsprung evaluation (when suspected). A contrast enema can support Hirschsprung disease evaluation by showing bowel pattern changes that suggest the diagnosis, usually followed by confirmatory biopsy. American Thoracic Society+1

Main Treatment Goal

For CCHS, the most important “treatment” is reliable breathing support, because medicines do not fix the core problem of automatic breathing control. The goal is to keep oxygen and CO₂ in safe ranges during sleep (and sometimes while awake), prevent repeated low-oxygen events, and protect the brain, heart, and lungs over time. This is why CCHS care is usually lifelong and involves a team (sleep/respiratory, pulmonology, ENT, cardiology, gastro/surgery, and genetics). PMC+2American Thoracic Society+2

Non-Pharmacological Treatments (Therapies and Others)

Sleep ventilation (home ventilator) + careful settings/backup rate: A ventilator gives breaths when the body forgets to breathe, especially during sleep. Purpose: prevent high CO₂ and low oxygen. Mechanism: positive pressure pushes air into the lungs on a schedule even when the brain’s drive is weak. PMC+2American Thoracic Society+2

Tracheostomy ventilation (when needed) + safe airway care: A tracheostomy is an opening in the neck connected to the windpipe for secure ventilation. Purpose: stable long-term breathing support (often in severe infancy). Mechanism: creates a direct airway path so the ventilator can deliver breaths reliably with less leak. PMC+1

Noninvasive ventilation (mask/BiPAP) + mask fit/skin protection: Some patients can use a mask instead of a trach, especially as they grow. Purpose: support breathing during sleep without surgery. Mechanism: bilevel pressure helps airflow and ventilation; good fit reduces leaks so CO₂ control improves. PMC+1

Diaphragm pacing + pacing training: Diaphragm pacing uses implanted electrodes to stimulate breathing muscles. Purpose: reduce ventilator dependence in selected patients. Mechanism: electrical stimulation activates the diaphragm rhythmically, creating breaths more naturally (but still requires careful monitoring). PMC+1

Regular sleep studies (polysomnography) + CO₂ monitoring: Testing is repeated over time because needs change with growth and illness. Purpose: confirm ventilation is truly controlling CO₂ and oxygen. Mechanism: sensors measure breathing flow, oxygen, and CO₂ so settings can be adjusted based on objective data. PMC+1

Continuous pulse oximetry when asleep + capnography when available: Home monitoring can catch silent drops in oxygen or rising CO₂. Purpose: early warning and safety. Mechanism: oximetry tracks oxygen saturation; capnography estimates CO₂ so caregivers can respond quickly if ventilation fails. American Thoracic Society+1

Emergency plan (written) + caregiver training (CPR/ventilator alarms): CCHS can become dangerous if equipment fails or during infections. Purpose: faster, safer response. Mechanism: a clear plan reduces delays; training helps caregivers troubleshoot alarms, tubing, masks, and power problems. PMC+1

Avoid breathing-depressant medicines + anesthesia planning: Many sedatives, opioids, and some sleep medicines can worsen hypoventilation. Purpose: prevent sudden CO₂ rise and dangerous sleep events. Mechanism: these drugs reduce brain breathing drive; planning with anesthesia teams prevents avoidable respiratory suppression. American Thoracic Society+1

Heart rhythm screening (Holter) + autonomic checkups: CCHS can affect heart rhythm and other automatic functions. Purpose: prevent fainting or rare dangerous rhythm problems. Mechanism: monitoring finds slow heart rate or pauses early so treatment (like pacing) can be considered if needed. PMC+1

Hirschsprung care pathway (if present): bowel program + early enterocolitis response: If Hirschsprung disease exists, constipation and bowel infection (enterocolitis) risk rises. Purpose: keep stool moving and treat dangerous bowel inflammation early. Mechanism: bowel routines and fast medical care reduce blockage, bacterial overgrowth, and severe illness. NIDDK+2PMC+2

Drug Treatments

Important safety note: These drugs are not “primary treatment” for CCHS breathing failure; ventilation is. Doses must be chosen by a licensed clinician (age/weight, other diseases, and monitoring matter a lot). PMC+1

 Caffeine citrate (Class: methylxanthine stimulant) + Theophylline (Class: methylxanthine): These can stimulate breathing in some settings (commonly neonatal apnea for caffeine), but they do not replace ventilation in CCHS. Typical label dosing for caffeine is for apnea of prematurity; timing is usually daily after a loading dose. Purpose: raise respiratory drive. Mechanism: blocks adenosine effects and increases central stimulation. Side effects: fast heart rate, feeding intolerance, jitteriness, seizures at high levels (rare). Office of Dietary Supplements+2FDA Access Data+2

Acetazolamide (Class: carbonic anhydrase inhibitor) + Medroxyprogesterone acetate (Class: progestin): Sometimes discussed as “ventilatory stimulants” in other hypoventilation problems, but CCHS usually still needs mechanical support. Dosing/timing are label-based for other indications and must be individualized. Purpose: support ventilation/CO₂ control in selected cases. Mechanism: acetazolamide causes mild metabolic acidosis that can increase ventilation; progestins can increase ventilatory drive. Side effects: electrolyte changes, kidney stones (acetazolamide); clot risk and hormonal effects (progestin). FDA Access Data+2FDA Access Data+2

Naloxone (Class: opioid antagonist) + Flumazenil (Class: benzodiazepine antagonist): These are emergency “reversal” medicines if opioids or benzodiazepines cause dangerous breathing suppression, which is especially risky in CCHS. Dosing is per FDA label and clinical emergency protocols; timing is immediate in emergencies. Purpose: reverse drug-related respiratory depression. Mechanism: blocks opioid or benzodiazepine effects at receptors. Side effects: acute withdrawal, seizures (rare), agitation. FDA Access Data+2FDA Access Data+2

Sildenafil (Revatio) (Class: PDE-5 inhibitor) + Bosentan (Tracleer) (Class: endothelin receptor antagonist): These may be used if pulmonary hypertension develops (a known risk when ventilation is not adequate). FDA labels describe dosing by indication; timing is often multiple daily doses. Purpose: lower pulmonary artery pressure and reduce strain on the right heart. Mechanism: relaxes pulmonary blood vessels (different pathways). Side effects: low blood pressure, headache; liver toxicity risk with bosentan (monitoring). FDA Access Data+2FDA Access Data+2

Epoprostenol (Flolan) (Class: prostacyclin) + Tadalafil (Adcirca) (Class: PDE-5 inhibitor): Used for more advanced pulmonary hypertension in selected patients. Dosing/timing follow label and specialist protocols (epoprostenol is continuous infusion). Purpose: improve pulmonary blood flow and symptoms. Mechanism: strong vasodilation and anti-platelet effects (prostacyclin pathway) or PDE-5 inhibition. Side effects: low blood pressure, flushing, jaw pain; catheter/infection risks with infusion therapy. FDA Access Data+2FDA Access Data+2

Furosemide (Lasix) (Class: loop diuretic) + Spironolactone (Class: aldosterone antagonist): If heart strain or fluid overload occurs (for example with pulmonary hypertension), diuretics can support symptoms. Dosing/timing are label-based and individualized (often daily or divided). Purpose: reduce edema and cardiac workload. Mechanism: increases salt/water excretion. Side effects: dehydration, electrolyte imbalance; spironolactone can raise potassium. FDA Access Data+2FDA Access Data+2

Lactulose (Class: osmotic laxative) + Bisacodyl (Class: stimulant laxative): These are supportive for constipation, which is common in Hirschsprung disease and can also be part of autonomic dysfunction care. Dosing/timing depend on age and stool pattern. Purpose: keep stool moving and reduce obstruction risk. Mechanism: lactulose draws water into bowel; bisacodyl stimulates bowel movement. Side effects: cramps, diarrhea, dehydration if overused. FDA Access Data+2FDA Access Data+2

 Metronidazole (Flagyl) (Class: antibiotic) + Amoxicillin/clavulanate (Augmentin) (Class: antibiotic): If Hirschsprung-associated enterocolitis is suspected, broad antibiotics are often part of urgent care (along with fluids and rectal irrigations). Doses/timing depend on severity and local protocols. Purpose: treat bowel infection/inflammation early. Mechanism: kills anaerobes (metronidazole) and broad bacteria (Augmentin). Side effects: nausea/diarrhea; allergy; C. difficile risk. Office of Dietary Supplements+2PMC+2

Ceftriaxone (Rocephin) (Class: cephalosporin antibiotic) + Azithromycin (Zithromax) (Class: macrolide antibiotic): Respiratory infections can destabilize ventilation needs in CCHS, so prompt evaluation and appropriate antibiotics (when bacterial infection is confirmed/suspected) matter. Dosing/timing are label-based and clinician-selected. Purpose: treat bacterial pneumonia/other infections. Mechanism: blocks bacterial cell wall (ceftriaxone) or protein synthesis (azithro). Side effects: diarrhea, rash, QT risk (azithro). FDA Access Data+2FDA Access Data+2

Oseltamivir (Tamiflu) (Class: antiviral) + Omeprazole (Prilosec) (Class: proton-pump inhibitor): Viral flu can worsen breathing stability; oseltamivir is used for influenza treatment/prophylaxis per label and clinical guidance. Reflux is common in many complex children; omeprazole may be used if GERD is diagnosed. Purpose: reduce flu severity (oseltamivir) and reduce acid injury (omeprazole). Mechanism: blocks viral neuraminidase; blocks stomach acid pump. Side effects: nausea (oseltamivir); low magnesium/B12 risk with long use (PPI). FDA Access Data+2FDA Access Data+2

Dietary Molecular Supplements (Supportive Only)

Important: Supplements do not treat the PHOX2B breathing-control problem. Use them only when a clinician says they are needed (for example, deficiency, poor intake, or specific risk). Office of Dietary Supplements+1

Vitamin D + Calcium (Dosage: per age/RDA; clinician-guided): Function: support bone strength, especially if mobility is limited or chronic illness affects nutrition. Mechanism: vitamin D helps the body absorb calcium and support normal muscle/nerve function. Too much can be harmful, so dose should follow guidance and blood tests when needed. Office of Dietary Supplements+1

Omega-3 fatty acids + Magnesium (Dosage: label/RDA-guided): Function: omega-3 supports general cardiovascular health; magnesium supports normal muscle and nerve function and can help if dietary intake is low. Mechanism: omega-3 affects cell membranes and inflammation signaling; magnesium is a key mineral for many enzymes. Side effects at high doses can include stomach upset/diarrhea. Office of Dietary Supplements+1

Probiotics + Soluble fiber (Dosage: product-specific; start low): Function: support gut health and stool regularity, especially when Hirschsprung care includes bowel routines. Mechanism: probiotics can help balance gut microbes; fiber holds water in stool and supports movement. Safety: in very ill or immunocompromised people, probiotics need medical advice first. Office of Dietary Supplements+2Office of Dietary Supplements+2

 Zinc + Selenium (Dosage: do not exceed upper limits): Function: support immune function when intake is poor. Mechanism: both are needed for normal immune cell activity and antioxidant enzymes. High-dose zinc can cause copper deficiency and stomach upset, so avoid “mega-dosing.” digitalmedia.hhs.gov+1

Vitamin C + B-complex (including B12/folate) (Dosage: RDA-guided): Function: support general nutrition and red blood cell/nerve health, especially if diet is limited. Mechanism: these vitamins act as enzyme helpers in energy and cell repair pathways. Supplements help most when there is a real deficiency; otherwise benefit can be small. Office of Dietary Supplements+1

Immunity Booster / Regenerative / Stem-Cell” Drugs — What Is Realistic

There is no FDA-approved stem-cell or regenerative drug that cures CCHS today; the proven lifesaving therapy remains ventilatory support and careful monitoring. The items below are advanced biologic medicines sometimes used to prevent or treat serious infections or immune problems in high-risk patients (not CCHS-specific), and only a specialist should decide if they fit. PMC+1

Nirsevimab (Beyfortus) + Palivizumab (Synagis) (Class: RSV monoclonal antibodies): Purpose: prevent severe RSV disease in infants/young children at risk. Mechanism: lab-made antibodies bind RSV and reduce infection severity. Dosing/timing are per FDA label and season/risk rules (single dose for nirsevimab; monthly doses for palivizumab). Side effects: injection reactions; rare allergy. FDA Access Data+1

Filgrastim (Neupogen) + Pegfilgrastim (Neulasta) (Class: G-CSF growth factors): Purpose: raise neutrophil counts in specific neutropenia settings (not routine for CCHS). Mechanism: stimulates bone marrow to make neutrophils. Dosing/timing are label-defined by indication. Side effects: bone pain, spleen enlargement (rare), allergic reactions (rare). FDA Access Data+1

Immune globulin (IVIG, example: Gammagard Liquid) + (General immune-support supplement guidance): Purpose: IVIG replaces antibodies in true immune deficiency and can reduce severe infections (not a CCHS treatment). Mechanism: provides pooled IgG antibodies from donors. Dosing/timing depends on indication; important risks include thrombosis and kidney problems in some patients, so specialists monitor carefully. U.S. Food and Drug Administration+1

Surgeries / Procedures — What They Are and Why They Are Done

1) Tracheostomy (procedure): Done when long-term secure ventilation is needed, often in severe early-life CCHS. It reduces airway leak and allows dependable ventilator connection. PMC+1

2) Diaphragm pacing implantation (procedure): Done in selected patients to stimulate breathing muscles and reduce ventilator dependence (still needs monitoring). PMC+1

3) Cardiac pacemaker (procedure, selected cases): Done if dangerous slow heart rhythms or long pauses occur due to autonomic dysfunction, to prevent fainting and rare life-threatening events. PMC+1

4) Hirschsprung “pull-through” surgery (procedure): Done to remove the bowel segment without nerve cells and connect healthy bowel to the anus, fixing blockage and reducing severe constipation. NIDDK+1

5) Ostomy (temporary or sometimes longer) (procedure): Done when the bowel needs diversion before/after pull-through or when the child is too sick for immediate repair; it helps stool pass safely. NIDDK+1

Prevention Tips (To Reduce Crises and Complications)

Preventing harm in CCHS mostly means preventing missed ventilation, preventing infections, and preventing medication mistakes. PMC+1

1) Use the ventilator exactly as prescribed during sleep; keep backup power, extra tubing/masks, and alarm checks; and re-check settings as the child grows. PMC+1
4) Avoid sedatives/opioids unless a specialist plans monitoring; keep an anesthesia alert letter; and tell every doctor/dentist “CCHS” before procedures. American Thoracic Society+1
7) Treat colds/fever early and watch oxygen/CO₂ closely during illness; keep vaccines up to date as advised by clinicians (infection prevention reduces decompensation risk). PMC+1
9) If Hirschsprung disease exists, follow bowel routines and seek urgent care for signs of enterocolitis (swollen belly, fever, explosive diarrhea, lethargy). NIDDK+1

When to See Doctors (Urgent and Routine)

Go to urgent care/emergency immediately if there is blue/gray color, severe sleepiness, repeated vomiting, breathing equipment failure you cannot fix quickly, oxygen stays low, or you suspect high CO₂ (unusual headache, confusion, extreme drowsiness). Seek urgent care for possible Hirschsprung enterocolitis signs (fever, belly swelling, sudden diarrhea, blood in stool, lethargy). Routine follow-up is needed for sleep/ventilation checks, heart rhythm screening, and growth/nutrition review even when the child seems “fine.” PMC+3PMC+3American Thoracic Society+3

What to Eat and What to Avoid

What to eat: (1) regular meals with enough protein for growth; (2) high-fiber foods if allowed by the Hirschsprung/surgery team; (3) fluids to prevent constipation; (4) calcium/vitamin-D rich foods for bones; (5) probiotic foods (like yogurt) if tolerated. This supports gut movement and overall strength, but bowel plans must match the child’s surgical status. NIDDK+2Office of Dietary Supplements+2

What to avoid/limit: (6) dehydration (can worsen constipation); (7) very constipating ultra-processed foods if Hirschsprung constipation is a problem; (8) unapproved “mega-dose” supplements (zinc, vitamins) without a clinician; (9) alcohol and sedating substances (dangerous for breathing control); (10) any new medicine that makes the child unusually sleepy unless a clinician confirms it is safe with CCHS monitoring. Office of Dietary Supplements+2digitalmedia.hhs.gov+2

FAQs

1) Is CCHS curable? No current cure; treatment controls breathing and complications long-term. PMC+1
2) What causes it? Usually a PHOX2B gene change affecting automatic breathing control. Genetic Disease Center+1
3) Why is sleep worse? Automatic breathing drive is weakest during sleep, so hypoventilation shows most clearly then. American Thoracic Society+1

4) Can a child look “normal” but still be at risk? Yes—oxygen/CO₂ problems can be silent without monitoring. PMC+1
5) Do inhalers cure CCHS? No; inhalers help airway disease, not brain breathing control. PMC+1
6) Do stimulants like caffeine replace a ventilator? No; they may help in other conditions but are not a replacement in CCHS. Office of Dietary Supplements+1

7) What is Haddad syndrome? CCHS plus Hirschsprung disease (bowel nerve-cell absence). PubMed+1
8) How is Hirschsprung treated? Usually surgery (pull-through), sometimes an ostomy first. NIDDK+1
9) What is Hirschsprung enterocolitis? A dangerous bowel inflammation/infection that needs urgent care. PMC+1

10) Why are heart checks needed? Autonomic problems can affect heart rhythm; screening helps prevent serious events. PMC+1
11) Can CCHS be inherited? It can be autosomal dominant, but many cases are new (de novo) changes. Genetic Disease Center+1
12) Will ventilation needs change over time? Yes—growth, illness, and development can change settings and support level. PMC+1

13) Is diaphragm pacing for everyone? No; it is for selected patients and still needs close monitoring. PMC+1
14) Are “stem cell drugs” proven for CCHS? No approved stem-cell/regenerative drug treats CCHS today. PMC+1
15) What improves long-term outcome most? Early diagnosis, reliable ventilation, monitoring, and a coordinated care team. PMC+2American Thoracic Society+2

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: December 17, 2025.